Kramer, Tilmann <br/><br/>
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.  [electronic resource] 

 -  International journal of cardiology  05 2019 
 - 152-158 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1874-1754 
<br/><br/><label>Standard No.: </label>10.1016/j.ijcard.2018.12.078  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Cardiac Catheterization<br/>Echocardiography<br/>Female<br/>Follow-Up Studies<br/>Heart Failure--complications<br/>Heart Ventricles--diagnostic imaging<br/>Humans<br/>Hypertension, Pulmonary--drug therapy<br/>Male<br/>Phosphodiesterase 5 Inhibitors--therapeutic use<br/>Retrospective Studies<br/>Stroke Volume--physiology<br/>Tadalafil--therapeutic use<br/>Time Factors<br/>Treatment Outcome<br/>Vascular Resistance--physiology<br/>Ventricular Function, Right--physiology